The fly..Amarin briefing docs 'lean toward narrow label,' says Goldman Sachs Goldman Sachs analyst Paul Choi noted that Amarin shares are indicated up in pre-market trading following the FDA releasing briefing documents for the Advisory Committee meeting on Thursday to review adding the REDUCE-IT indication to the Vascepa label. However, he expects the stock to revert lower as he believes the docs are "at odds" with the broad label being sought by the company. The briefing documents indicated that FDA staff said "the trial inclusion criteria and data do not appear to support such a broad population" as the one being sought by Amarin, stated Choi. Based on the briefing documents, he still sees a high likelihood of a positive vote, but in a subset of patients compared to what Amarin is seeking, said Choi, who keeps a Neutral rating and $17 price target on Amarin shares. At time of writing, the stock is up $2.52, or 15%, to $19.43.
Market Data 
Markets 
AI
